Updated (3/12/20) Shiseido Plans To Pursue RCH-01
Directly from Shiseido’s “New Research”
webpage regarding the RCH-01 therapy:
“Safety level and improvement effects were confirmed in a clinical study conducted by Tokyo Medical University from 2016 to 2019 using our autologous cell culture processing technology. A further clinical study aiming at practical application will be conducted in the future.”
https://www.folliclethought.com/shis...-results-2020/
---
Wel al een tijdje geleden maar Follica heeft een patent geplaatst met hun regime. Als alles goed gaat zou dit volgend jaar op de markt moet komen.
- The primary target is to produce 1600 thin needle wounds per cm² every two weeks (their preferred parameter configuration is: using a 12 needle head (2 rows with 6 needles) with a width of 0.9 cm at a movement speed of 2 cm per second and an osicllation speed of 120 Hz)
- Needling device: electric dermaneedling device. They specifically state that dermarollers and dermabrasion devices are less effective. About dermarollers they write that tearing and cut-like wounds are ineffective for neogenesis and that one has to aim for real, "pointy" needle wounds without any tearing or cutting.
- Needle target depth: 0.8 mm. For long hair, this can be increased to 1.0 mm, but definitely not more than that. The wound should extend 0.8 mm into the skin but not deeper, 1.0 mm is only to compensate for longer hair.
- Needling frequency: Once every two weeks produces the best results, followed by once a week, followed by once every 4 weeks
- Needling head: 12 needles in an array of 2 x 6 at a width of 0.9 cm for the needle rows. Their specific design is described in Figure 105 of this patent of theirs
- Topical, 1st version: minoxidil 5% is the likely first version of the topical (maybe also finasteride or saw palmetto included, but about this I'm not sure)
- Topical, 2nd version: The second version of the topical is minoxidil plus one or a combination of the following three: finasteride, valproic acid, latanoprost
- Topical application frequency: Twice daily, preferrably once every 12 hours
- Areas to needle: Not only affected areas should be needled, but also at least 2 cm into non-bald/non-balding areas. Reason for that is probably quorum sensing.
- Needling device movement over the scalp: Each area should be covered at least once and at most twice, depending on the protocol variant. Depends on frequency and a few other things - won't go into detail here now, the details can be found in the patent. Short version: In the preferred protocol, each treatment area is covered once in horizontal and once in vertical movement direction over the scalp, making for a total of exactly two passes. Passes should be performed without any overlaps and without any gaps. They use the term "like a lawn mower" several times to describe how the scalp should be covered.
- Needling movement speed: 2 cm per second. They state that the translational movement speed is important to achieve the target needle hole density of 1600 per cm².
- Needling head oscillation frequency: 120 Hz
- Needling pressure: Only slight pressure such that the needles go all the way (0.8 mm) in, but not more. "Gliding" should be achieved.
---
Ben ook benieuwd voor Samumed, deze gaan een WNT agonist topical op de markt brengen en deze zou uitkomen in 2022